Novavax News

Novavax | 8-K: Investor Presentation

Jan 13 20:52

Novavax | 8-K: Asset Purchase Agreement

Dec 31, 2024 06:30

Novavax | 8-K: Amendment No. 5 to the Advance Purchase Agreement

Dec 19, 2024 06:29

Novavax | 8-K: Asset Purchase Agreement

Dec 4, 2024 19:07

Novavax | 8-K: Investor Presentation

Nov 21, 2024 01:57

Novavax | 8-K: U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Nov 13, 2024 00:24

Novavax | 8-K: Settlement Agreement

Nov 6, 2024 06:06

Novavax | 8-K: Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial

Oct 16, 2024 20:02

Novavax | 8-K: Regulation FD Disclosure

Oct 4, 2024 02:51

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Aug 9, 2024 04:21

Novavax | 8-K: Poll Results of 2024 Stockholders Meeting

Jun 15, 2024 04:07

Novavax | 8-K: Investor Presentation of Novavax, Inc.

Jun 6, 2024 19:01

Novavax | DEFA14A: Others

Jun 5, 2024 18:06

Novavax | 8-K: R&D President Filip Dubovsky Resigns

May 24, 2024 04:12

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 21, 2024 02:45

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 14, 2024 04:15

Novavax | 8-K: Collaboration and License Agreement

May 14, 2024 02:44

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 9, 2024 04:57

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 8, 2024 05:26

Novavax | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

May 7, 2024 04:45